FDA honored by IoM
This article was originally published in The Tan Sheet
The Institute of Medicine has made FDA Commissioner Mark McClellan, MD/PhD, and Deputy Commissioner Lester Crawford, PhD, its newest members, the agency announces Oct. 27. The holders of the agency's top two positions have never been asked to join the National Academy of Sciences division at the same time, FDA adds. "New IoM members are chosen worldwide on the basis of their distinguished professional achievement in a field related to medicine and health, and on their involvement in health care, disease prevention, education and research," FDA adds...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”